Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment-resistant and ultratreatment-resistant schizophrenia

被引:11
|
作者
Kitajima, Kazutoshi [1 ]
Tamura, Shunsuke [1 ]
Sasabayashi, Daiki [2 ,3 ]
Nakajima, Shinichiro [4 ,5 ]
Iwata, Yusuke [5 ,6 ]
Ueno, Fumihiko [5 ]
Takai, Yoshifumi [1 ]
Takahashi, Junichi [1 ,7 ]
Caravaggio, Fernando [5 ]
Mar, Wanna [5 ]
Torres-Carmona, Edgardo [5 ,8 ]
Noda, Yoshihiro [4 ]
Gerretsen, Philip [5 ,8 ]
de Luca, Vincenzo [5 ,8 ]
Mimura, Masaru [4 ]
Hirano, Shogo [1 ]
Nakao, Tomohiro [1 ]
Onitsuka, Toshiaki [1 ]
Remington, Gary [5 ,8 ]
Graff-Guerrero, Ariel [5 ,8 ]
Hirano, Yoji [1 ,9 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka, Japan
[2] Univ Toyama, Dept Neuropsychiat, Grad Sch Med & Pharmaceut Sci, Toyama, Japan
[3] Univ Toyama, Res Ctr Idling Brain Sci, Toyama, Japan
[4] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[5] Ctr Addict & Mental Hlth CAMH, Res Imaging Ctr, Toronto, ON, Canada
[6] Univ Yamanashi, Dept Neuropsychiat, Fac Med, Kofu, Yamanashi, Japan
[7] Natl Hosp Org Kyushu Med Ctr, Dept Neuropsychiat, Fukuoka, Fukuoka, Japan
[8] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[9] Univ Tokyo, Inst Ind Sci, Tokyo, Japan
基金
加拿大健康研究院;
关键词
gyrification; surface area; treatment-resistant schizophrenia; PSYCHOTIC DISORDERS; TREATMENT RESPONSE; THICKNESS; ABNORMALITIES; HYPOTHESIS; CLOZAPINE; SYMPTOMS; CAPACITY; VOLUME; MODEL;
D O I
10.1111/pcn.13482
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aim: Validating the vulnerabilities and pathologies underlying treatment-resistant schizophrenia (TRS) is an important challenge in optimizing treatment. Gyrification and surface area (SA), reflecting neurodevelopmental features, have been linked to genetic vulnerability to schizophrenia. The aim of this study was to identify gyrification and SA abnormalities specific to TRS. Methods: We analyzed 3T magnetic resonance imaging findings of 24 healthy controls (HCs), 20 responders to first-line antipsychotics (FL-Resp), and 41 patients with TRS, including 19 clozapine responders (CLZ-Resp) and 22 FL- and clozapine-resistant patients (patients with ultratreatment-resistant schizophrenia [URS]). The local gyrification index (LGI) and associated SA were analyzed across groups. Diagnostic accuracy was verified by receiver operating characteristic curve analysis. Results: Both CLZ-Resp and URS had lower LGI values than HCs (P = 0.041, Hedges g [g(H)] = 0.75; P = 0.013, g(H) = 0.96) and FL-Resp (P = 0.007, g(H) = 1.00; P = 0.002, g(H) = 1.31) in the left medial parietal cortex (Lt-MPC). In addition, both CLZ-Resp and URS had lower SA in the Lt-MPC than FL-Resp (P < 0.001, g(H) = 1.22; P < 0.001, g(H) = 1.75). LGI and SA were positively correlated in non-TRS (FL-Resp) (rho = 0.64, P = 0.008) and TRS (CLZ-Resp + URS) (rho = 0.60, P < 0.001). The areas under the receiver operating characteristic curve for non-TRS versus TRS with LGI and SA in the Lt-MPC were 0.79 and 0.85, respectively. SA in the Lt-MPC was inversely correlated with negative symptoms (rho = -0.40, P = 0.018) and clozapine plasma levels (rho = -0.35, P = 0.042) in TRS. Conclusion: LGI and SA in the Lt-MPC, a functional hub in the default-mode network, were abnormally reduced in TRS compared with non-TRS. Thus, altered LGI and SA in the Lt-MPC might be structural features associated with genetic vulnerability to TRS.
引用
收藏
页码:2 / 11
页数:10
相关论文
共 50 条
  • [1] Cariprazine: Patients with Treatment-Resistant Schizophrenia
    Aubel, Thomas
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2327 - 2332
  • [2] Management of treatment-resistant patients with schizophrenia
    Marder, SR
    JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 : 26 - 30
  • [3] CLOZAPINE POLYPHARMACY IN TREATMENT-RESISTANT SCHIZOPHRENIA PATIENTS
    Lerner, Vladimir
    Miodownik, Chanoch
    ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, 2012, 49 (01): : 47 - 47
  • [4] Altered functional connectivity in anterior cingulate cortex subregions in treatment-resistant schizophrenia patients
    Liu, Ying
    Huang, Huan
    Qin, Xucong
    Zheng, Fanfan
    Wang, Huiling
    NEUROSCIENCE LETTERS, 2023, 814
  • [5] Treatment-resistant Schizophrenia and Global Cortical Atrophy in a Patient with Turner Syndrome
    Langgartner, S.
    Strube, W.
    Oviedo, T.
    Hansbauer, M.
    Karch, S.
    Wirth, S.
    Falkai, P.
    Hasan, A.
    PHARMACOPSYCHIATRY, 2016, 49 (06) : 262 - 263
  • [6] Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
    Kane, JM
    Khanna, S
    Rajadhyaksha, S
    Giller, E
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (01) : 21 - 28
  • [7] Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia
    Ucok, Alp
    Yagcioglu, Elif Anil
    Yildiz, Mustafa
    Kaymak, Semra Ulusoy
    Saka, Meram Can
    Tasdelen, Rumeysa
    Danaci, Aysen Esen
    Senol, Sevin Hun
    PSYCHIATRY RESEARCH, 2019, 275 : 149 - 154
  • [8] Profiling cognitive impairment in treatment-resistant schizophrenia patients
    Frydecka, Dorota
    Beszlej, Jan Aleksander
    Goscimski, Piotr
    Kiejna, Andrzej
    Misiak, Blazej
    PSYCHIATRY RESEARCH, 2016, 235 : 133 - 138
  • [9] Evaluating sexual function in patients with treatment-resistant schizophrenia
    Kelly, DL
    Conley, RR
    SCHIZOPHRENIA RESEARCH, 2003, 63 (1-2) : 195 - 196
  • [10] Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia
    Hashimoto, K.
    Sudo, T.
    Hirano, M.
    Motomura, H.
    Tagawa, K.
    Nashiro, S.
    Uemura, K.
    Yoshimoto, S.
    SCHIZOPHRENIA RESEARCH, 2006, 87 (1-3) : 332 - 333